Intended Audience: Physicians, Nurse Practitioners, Physician Assistants, Pharmacists, Nurses, and Case Managers
Recent years have brought many updates in the world of asthma. But what does this mean for your patients? Stream this CE-accredited webcast to hear from the experts how you and your team can apply the latest advances in personalized asthma treatment and patient-centered care. Case-based content will allow you to exercise your problem-solving skills for complex patients with moderate-to-severe asthma while picking up some new pointers to ensure that your patients have access to the right therapy at the right time.
Physicians completing this program will earn AMA PRA Category 1 Credit™ classified as Enduring material.
Pharmacists completing this program will earn Home Study credit in Disease State Mgmt/Drug therapy (H01).
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing primeinc.org, please email firstname.lastname@example.org for assistance. Please put “ADA Inquiry” in the subject line of your email.
Activity Type:OnlineRelease Date:July 1, 2019Expiration Date:June 30, 2020Total Price:Free
Continuing Education Credits:
- 1.0 CE for Physicians (AMA Category 1)
- 1.0 CE for Physician Assistants
- 1.0 CE for Nurse Practitioners
- 1.0 CE for Pharmacists (Automatic NABP)
- 1.0 CE for Nurses
- 1.0 CE for Case Managers (CCMC)
• Estimated time to complete: 60 minutes
• Content last reviewed July 1, 2019.
• You do not need to complete in one sitting.
Michael E Wechsler, MD, MMScDirector, The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Jose L Alejandro, PhD, RN-BC, MBA, FACHE, FAANPresident
Case Management Society of America (CMSA)
Michelle T Martin, PharmD, FCCP, BCPS, BCACPClinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
Fink Family Liver Clinic
University of Illinois Hospital and Health Sciences System
Allan J Chernov, MDMedical Director (Retired)
Mid-Markets and Medical Policy
Blue Cross and Blue Shield of Texas (BCBSTX)
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCNNational Clinical Nursing Director
Multiple Sclerosis Center of Excellence East
Veterans Affairs Medical Center
Kathleen A Jarvis, MS, RN, CCMNurse Case Manager
Cape Elizabeth, ME
Michele B Kaufman, PharmD, BCGPPharmacist
New York Presbyterian Hospital – Lower Manhattan
New York, NY
Joyce M Knestrick, PhD, CRNP, FAANPAssociate Professor
Family Nurse Practitioner
Wheeling Health Right
I. Defining New Concepts in Asthma Pathogenesis, Comorbidities, and Treatment Targets
II. Late-Breaking Updates on the Efficacy and Safety of New and Emerging Targeted Therapies
III. Developing Personalized Treatment Plans for Patients with Moderate-to-Severe Asthma
IV. Leveraging Interprofessional Strategies for Optimal Treatment, Referrals, and Care Coordination
- Summarize the role of type 2 inflammation in the pathogenesis of asthma and atopic comorbidities
- Differentiate the indications, efficacy and safety profiles, and utility of new and emerging biologic therapies for uncontrolled, moderate-to-severe asthma
- Implement guideline-directed referrals and enhance care coordination strategies for patients with moderate-to-severe asthma, including patients with atopic comorbidities
- Develop collaborative strategies for navigating health plans to ensure that patients with uncontrolled, moderate-to-severe asthma receive needed therapies without delay